Zofran Heart Defects Risk in Newborns Reflected in January Case Study

Published on March 4, 2015 by Sandy Liebhard

Text-Size:A A A+

 

The deaths of two children who were given an anti-nausea medication often prescribed to pregnant women are being attributed to Zofran heart defects in a study published at the end of January.

Results of the research were published January 26, 2015 in Pediatric Emergency Care and involve reports on two children who suffered heart problems that followed use of the medication. In the first case, a 10-year-old boy who was otherwise healthy but came into the emergency room with symptoms of gastroenteritis, a condition commonly known as the stomach flu and was given two doses of Zofran to treat his symptoms. He was also given an IV, morphine and antibiotics, according to the research. It was after he took the Zofran, however, that the boy became unresponsive and began showing signs of tachycardia, which refers to a faster-than-normal heart rate. The second case also involved use of this medication in a child with stomach flu symptoms. The difference was that he was only 86 days old, but he also developed tachycardia problems and eventually died. Women whose children were born with similar side effects may be eligible to pursue a Zofran lawsuit.

Zofran Heart Defects Noted in Several Complaint Reports

Zofran is known as a 5-HT3 receptor antagonist, and is used in the treatment of extreme nausea and vomiting. In 1991, the drug was approved by the U.S. Food and Drug Administration (FDA) for chemotherapy and surgery patients but has not been officially cleared for use in pregnant women. Nevertheless, Zofran is prescribed for these individuals, and a number of studies suggest that the result could be damaging to the baby being carried. Instances of Zofran heart and kidney defects, cleft lip and palates and fetal death have also been associated with the medication in a number of adverse event reports filed with the drug’s manufacturer, GlaxoSmithKline. What’s troubling about Zofran risks in newborns is that its manufacturer has admitted the lack of safety established for pregnant women. According to a report published in June 2014 by the Toronto Star, Zofran was linked to heart and kidney problems of newborns born to 20 women in the same year. A study published in a 2011 echoed these findings in a report that found a doubled risk for cleft palates in babies born to Zofran mothers.

Consider Legal Action against Zofran’s Manufacturer

Contact a Zofran attorney today to learn about the legal process of filing a complaint against GlaxoSmithKline. Call us now at .

Web Analytics